Explore
Companies
Investors
Top 50
Streams
Trending tech news
Latest investments
Latest acquisitions
About Index
Index
By TNW
Log in
Register
Oragenics
3199
Oragenics
Technology
Biotechnology
Health Care
Medical
Pharmaceuticals
We are a biopharmaceutical company focused primarily on oral probiotics products and novel antibiotics for humans and companion pets.
Suggest edits
Type
B2b
Founded
1996
Raised
$7.7M
Follow us
Companies in the same industry
Vaxess Technologies
Oncothyreon
Tricida, Inc.
Discuva Ltd
Otsuka Pharmaceutical Company Limited
Arbutus Biopharma
Kallyope
Biond Solutions (BI/OND)
Brii Biosciences
Antios Therapeutics
Alexa global traffic share
Twitter followers
Overview
Funding
2
Add info
Latest funding
$3,000,000
Post-IPO equity - 2017
$4,670,000
Venture capital - 2016
Team Size
1–10
Employees
I work here
Location
United States
Headquarters
Explore United States
Pulse 2.0
Oragenics Stock (OGEN): Why The Price Surged Today
Pulse 2.0
Oragenics Stock (OGEN): Why The Price Increased
$3,000,000
Post-IPO equity
businesswire
Oragenics Announces Completion of Second Closing of $3.0 Million Preferred Stock Private Placement
